This archive contains the following articles listed by volume, issue and page number:
 |
|
|
| Volume 19, 2015 Articles |
| Title (Click for Details) |
Vol/Issue |
Page |
| PreScription: 2014 in Review |
Vol. 19 No. 1 |
4 |
| Efficacy and Clinical Value of Commonly Compounded Hormone Replacement Therapy: A Literature Review |
Vol. 19 No. 1 |
6 |
| Giving Back: A Win-Win Plan of Action for Compounding Pharmacists |
Vol. 19 No. 1 |
14 |
| Pharmacy Student Survey: Perceptions and Expectations of Pharmaceutical Compounding |
Vol. 19 No. 1 |
18 |
| Agar Transfer Devices for Environmental Sampling in the Compounding Pharmacy: Science and Compliance |
Vol. 19 No. 1 |
30 |
| Biotechnology, Nanotechnology, and Pharmacogenomics and Pharmaceutical Compounding, Part 1 |
Vol. 19 No. 1 |
38 |
| Quality Control Analytical Methods: Refractive Index |
Vol. 19 No. 1 |
43 |
| Basics of Sterile Compounding: Aseptic Processing |
Vol. 19 No. 1 |
49 |
| Basics of Compounding: The Revised "Not to Compound List" |
Vol. 19 No. 1 |
57 |
| Calculations |
Vol. 19 No. 1 |
59 |
| Atenolol 25-, 50-, or 100-mg Capsules |
Vol. 19 No. 1 |
60 |
| Azathioprine 50-mg Capsules |
Vol. 19 No. 1 |
61 |
| Cisplatin 1-mg/mL Injection |
Vol. 19 No. 1 |
62 |
| Daunorubicin 5-mg/mL Injection |
Vol. 19 No. 1 |
63 |
| Erythromycin 50-mg/mL Injection |
Vol. 19 No. 1 |
64 |
| Hydralazine Hydrochloride 20-mg/mL Injection |
Vol. 19 No. 1 |
65 |
| Hydroxychloroquine Sulfate 200-mg Capsules |
Vol. 19 No. 1 |
66 |
| Lidocaine Hydrochloride 4% Topical Solution |
Vol. 19 No. 1 |
67 |
| Mupirocin 2% Ointment |
Vol. 19 No. 1 |
68 |
| Phentolamine Mesylate 5-mg/mL Injection |
Vol. 19 No. 1 |
69 |
| Stability Assessment of Repackaged Bevacizumab for Intravitreal Administration |
Vol. 19 No. 1 |
70 |
| Physicochemical and Microbiological Stability of Azathioprine in InOrpha Suspending Agent Studied Under Various Conditions |
Vol. 19 No. 1 |
73 |
| Stability of Suspensions: Theoretical and Practical Considerations before Compounding |
Vol. 19 No. 1 |
78 |
| PostScription: Pharmacists Advancing Toward Provider Status |
Vol. 19 No. 1 |
86 |
| PreScription: Some of the Best Sermons are Lived, not Preached! |
Vol. 19 No. 2 |
92 |
| New England Compounding Center Indictment |
Vol. 19 No. 2 |
94 |
| Standing Together Fixing the Drug Quality and Security Act |
Vol. 19 No. 2 |
104 |
| Standarized Compounding: The Importance of Doing it the Same Way Every Time |
Vol. 19 No. 2 |
109 |
| Bedside Manner: Not Just for Doctors Anymore |
Vol. 19 No. 2 |
115 |
| Quality Assurance and Quality Control, Part 1 |
Vol. 19 No. 2 |
121 |
| Basics of Sterile Compounding: Sterilization Methods in Sterile Product Manufacturing |
Vol. 19 No. 2 |
127 |
| Calculations |
Vol. 19 No. 2 |
140 |
| Acne Scrub |
Vol. 19 No. 2 |
142 |
| Aminohippurate Sodium 200-mg/mL Injection |
Vol. 19 No. 2 |
143 |
| Deferoxamine Mesylate 213/mg/mL or 95-mg/mL Injection |
Vol. 19 No. 2 |
144 |
| Heparin 335-United/Gram Gel-Cream |
Vol. 19 No. 2 |
145 |
| L-Cysteine Hydrochloride 50-mg/mL Injection |
Vol. 19 No. 2 |
146 |
| Morrhuate Sodium 5% Injection |
Vol. 19 No. 2 |
147 |
| Oxycodone Hydrochloride 5-mg and Acetaminophen 325-mg per 5-mL Oral Solution |
Vol. 19 No. 2 |
148 |
| Pancuronium Bromide 1-mg/mL Injection |
Vol. 19 No. 2 |
149 |
| Physostigmine Salicylate 1-mg/mL Injection |
Vol. 19 No. 2 |
150 |
| Trypan Blue 0.06% Ophthalmic Solution |
Vol. 19 No. 2 |
151 |
| Transdermal Delivery of Nisoldipine: Refinement of Vehicles |
Vol. 19 No. 2 |
152 |
| Skin Permeation and Antinociception of Compounded Topical Cyclobenzaprine Hydrochloride Formulations |
Vol. 19 No. 2 |
161 |
| Analgesic Efficacy and Transdermal Penetration of Topical Gabapentin Creams: Finding an Optimal Dose and Pre-treatment Time |
Vol. 19 No. 2 |
167 |
| PostScription: What's Your Patient Care Story? |
Vol. 19 No. 2 |
174 |
| PreScription: 2015 Student Pharmacist Compounding Competition |
Vol. 19 No. 3 |
180 |
| Dry-heat Depyrogenation Ovens for Pharmaceutical Compounding Facilities |
Vol. 19 No. 3 |
182 |
| Compounded Testosterone Troches to optimize Health and the Testosterone Controversy |
Vol. 19 No. 3 |
195 |
| Practicing Your Compounding Skills Outsides of Your Pharmacy's Walls |
Vol. 19 No. 3 |
205 |
| IACP Says: "Fix DQSA" |
Vol. 19 No. 3 |
212 |
| Quality Assurance and Quality Control, Part 2 |
Vol. 19 No. 3 |
215 |
| Basics of Compounding: Compounding with Silicones |
Vol. 19 No. 3 |
223 |
| Basics of Sterile Compounding: Contamination Control |
Vol. 19 No. 3 |
232 |
| Calculations |
Vol. 19 No. 3 |
240 |
| Atropine Sulfate 1% Ophthalmic Solution |
Vol. 19 No. 3 |
242 |
| Lidocaine Hydrochloride 2% Viscous Oral Topical Solution |
Vol. 19 No. 3 |
243 |
| Methylphenidate Hydrochloride 2.5-mg, 5-mg, or 10-mg Chewable Troches |
Vol. 19 No. 3 |
244 |
| Phenazopyridine Hydrochloride 200-mg Capsules |
Vol. 19 No. 3 |
245 |
| Physostigmine Salicylate 1-mg/mL Injection |
Vol. 19 No. 3 |
246 |
| Scopolamine Hydrobromide -.4-mg/mL Injection |
Vol. 19 No. 3 |
247 |
| Stability of Metronidazole Suspensions |
Vol. 19 No. 3 |
248 |
| Protocol of Blood Serum Eye Drops |
Vol. 19 No. 3 |
252 |
| Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials |
Vol. 19 No. 3 |
261 |
| PreScription: Potpourri of Opinions…From Many |
Vol. 19 No. 4 |
266 |
| Safer Sterile Compounding: Choosing and Using Disinfectants for the Cleanroom |
Vol. 19 No. 4 |
268 |
| Long-term Stability of Cocaine Hydrochloride Aqueous Solution 50 mg/mL (5%) at Room Temperature and at 5°C ± 3°C in Glass Bottles |
Vol. 19 No. 3 |
268 |
| PostScription: Opportunities to Change the Pharmacy Landscape |
Vol. 19 No. 3 |
271 |
| Biotechnology, Nanotechnology, and Pharmacogenomics and Pharmaceutical Compounding, Part 2 |
Vol. 19 No. 4 |
280 |
| Estradiol: The Emerging Evidence for a Protective Role Against Insulin Resistance and Obesity |
Vol. 19 No. 4 |
289 |
| Efficacy and Clinical Value of Commonly Used Ingredients in Pain Management Compounds: A Literature Review |
Vol. 19 No. 4 |
295 |
| U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances |
Vol. 19 No. 4 |
303 |
| Quality Control Analytical Methods: Physical Quantitative Verification of Nonsterile Compounded Preparations: Individualized Dosage Units |
Vol. 19 No. 4 |
307 |
| Basics of Compounding: The "Negative" List |
Vol. 19 No. 4 |
311 |
| Basics of Sterile Compounding: Barrier Isolator Technologist in Aseptic Processing |
Vol. 19 No. 4 |
315 |
| Calculations |
Vol. 19 No. 4 |
322 |
| Ammonium Molybdate 25-mcg/mL Injection |
Vol. 19 No. 4 |
324 |
| Balsam Peru, Castor Oil, and Trypsin Ointment |
Vol. 19 No. 4 |
325 |
| Benzonatate 100-mg Capsules |
Vol. 19 No. 4 |
326 |
| Chloroquine Phosphate 250-mg Capsules |
Vol. 19 No. 4 |
327 |
| Cytarabine 50-mg/mL Injection |
Vol. 19 No. 4 |
328 |
| Moxifloxacin Hydrochloride 1.6-mg/mL Intravenous Injection |
Vol. 19 No. 4 |
329 |
| Oxytocin 10-units/mL Injection |
Vol. 19 No. 4 |
330 |
| Phytonadione 2-mg/mL Injection |
Vol. 19 No. 4 |
331 |
| Proparacaine Hydrochloride 0.5% Ophthalmic Solution |
Vol. 19 No. 4 |
332 |
| Tacrolimus Capsules, 0.5 mg, 1 mg, or 5 mg |
Vol. 19 No. 4 |
333 |
| Use of 8.4% Sodium Bicarbonate in Buffering Commonly Administered Vancomycin Hydrochloride Solutions for Use with Midline or Peripheral Line Catheters |
Vol. 19 No. 4 |
334 |
| Stability of Prednisone in Oral Mix Suspending Vehicle |
Vol. 19 No. 4 |
337 |
| Development and Validation of an Inexpensive, Simple, and Rapid Technique for Measuring the Accuracy of Extemporaneously Compounded Pharmaceuticals |
Vol. 19 No. 4 |
340 |
| Stability of Diphenhydramine Hydrochloride, Lorazepam, and Dexamethasone Sodium Phosphate in 0.9% Sodium Chloride Stored in Polypropylene Syringes |
Vol. 19 No. 4 |
344 |
| PostScription: APhA2015: You Spoke, We Listened, and What a Success! |
Vol. 19 No. 4 |
348 |
| PreScription: Failure or Success? |
Vol. 19 No. 5 |
354 |
| Novel Approaches to Topical Psoriasis Therapy |
Vol. 19 No. 5 |
357 |
| Compounding Pharmacies' Potential to Create Graft Storage Solutions for Bypass Surgeries |
Vol. 19 No. 5 |
367 |
| The International Academy of Compounding Pharmacists Comments to the Draft Memorandum of Understanding |
Vol. 19 No. 5 |
375 |
| The Evolution of 21 CFR Parts 210 & 211 for Drug Compounders: An Unspoken Opportunity for Pharmacists |
Vol. 19 No. 5 |
377 |
| Using Hospital Laboratory Services to Perform Quality-control Testing on Compounded Preparations |
Vol. 19 No. 5 |
383 |
| Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1 |
Vol. 19 No. 5 |
389 |
| Sterile Filtration |
Vol. 19 No. 5 |
393 |
| Calculations |
Vol. 19 No. 5 |
402 |
| Aminocaproic Acid 250-mg/mL Oral Solution |
Vol. 19 No. 5 |
404 |
| Betamethasone Valerate 0.12%, Tranilast 1% Topical Gel |
Vol. 19 No. 5 |
405 |
| Lidocaine 2%, Metronidazole 2%, Misoprostol 0.0024% Topical Ointment |
Vol. 19 No. 5 |
406 |
| Nimodipine 3-mg/mL Oral Solution |
Vol. 19 No. 5 |
407 |
| Ofloxacin 0.3% Otic Solution |
Vol. 19 No. 5 |
408 |
| Povidone Iodine 10% Cold Sore Paint |
Vol. 19 No. 5 |
409 |
| Trichloroacetic Acid 20%, Salicylic Acid 20%, Lactic Acid 10% in Flexible Collodion |
Vol. 19 No. 5 |
410 |
| Vehicle for Oral Solution (National Formulary 26) |
Vol. 19 No. 5 |
411 |
| Vehicle for Oral Solution, Sugar Free (National Formulary 26) |
Vol. 19 No. 5 |
412 |
| Vehicle for Oral Suspension (National Formulary 26) |
Vol. 19 No. 5 |
413 |
| Solid State Stability of Extemporaneously Prepared Levothyroxine Aliquots and Capsules |
Vol. 19 No. 5 |
414 |
| Stability Assessment of 10 Active Pharmaceutical Ingredients Compounded in SyrSpend SF |
Vol. 19 No. 5 |
420 |
| Stability of Levothyroxine, Doxycycline, Hydrocortisone, and Pravastatin in Liquid Dosage Forms Stored at Two Temperatures |
Vol. 19 No. 5 |
428 |
| In-use Stability of Ceftaroline Fosamil in Elastomeric Home Infusion Systems and MINI-BAG Plus Containers |
Vol. 19 No. 5 |
432 |
| PostScription: Progress Report: Provider Status Continues to Gain Strength! |
Vol. 19 No. 5 |
437 |
| PreScription: The Documented Past and the Exciting Future |
Vol. 19 No. 6 |
442 |
| Clinical Perspectives in Compounding: Compounding Gains and Losses Since I Met "Careless Arithmetic Nullifies Careful Compounding" |
Vol. 19 No. 6 |
444 |
| International Academy of Compounding Pharmacists' Legislative Regulatory Update: Take Action! Stop the U.S. Good and Drug Administration's Misguided Veterminary Guidance |
Vol. 19 No. 6 |
449 |
| Applying Quality of Design Concepts to Pharmacy Compounding |
Vol. 19 No. 6 |
453 |
| Root Cause Analysis, Part 1: Nonsterile Compounding |
Vol. 19 No. 6 |
465 |
| Basic Principles of Lyophilization, Part 1 |
Vol. 19 No. 6 |
471 |
| Mixing in a Compounding Pharmacy in the 21st Century |
Vol. 19 No. 6 |
479 |
| U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs |
Vol. 19 No. 6 |
487 |
| Basics of Sterile Compounding: Sterile Product Packaging and Delivery Systems |
Vol. 19 No. 6 |
491 |
| Calculations |
Vol. 19 No. 6 |
502 |
| Acetominophen and Codeine Phosphate (300-mg/30-mg) Capsules |
Vol. 19 No. 6 |
504 |
| Cefepime Hydrochloride 100-mg/mL Injection |
Vol. 19 No. 6 |
505 |
| Cefotaxime 100-mg/mL Injection |
Vol. 19 No. 6 |
506 |
| Chlorpromazine Hydrochloride 25-mg/mL Injection, Preserved |
Vol. 19 No. 6 |
507 |
| Dexamethasone Sodium Phosphate Ophthalmic Solution: Equivalent to 0.1% Dexamethasone Phosphate |
Vol. 19 No. 6 |
508 |
| Estradiol Valerate 40-mg/mL in Oil Injection |
Vol. 19 No. 6 |
509 |
| Levetiracetam 100-mg/mL Injection (Concentrate) |
Vol. 19 No. 6 |
510 |
| Memantine Hydrochloride Capsules |
Vol. 19 No. 6 |
511 |
| Mupirocin 2% Nasal Ointment |
Vol. 19 No. 6 |
512 |
| Propranolol Hydrochloride Capsules |
Vol. 19 No. 6 |
513 |
| Pharmacists' Perceptions of the Economic Value of Compounded Pharmaceuticals: A Comparison of Compounded and Commercial Pharmaceuticals in Select Disease States |
Vol. 19 No. 6 |
514 |
| Long-term Stability of Esomeprazole in 5% Dextrose Infusion Polyolefin Bags at 5°C ± 3°C after Microwave Freeze-thaw Treatment |
Vol. 19 No. 6 |
521 |
| PostScription: Pharmacy Fellowship Program: Building a Stronger Profession |
Vol. 19 No. 6 |
525 |
